Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16141904 | 0.88 | POLB (0.38) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL331908 | 0.82 | NPSR1 (0.50) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL231396 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL485571 | 0.80 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL240008 | 0.80 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL28766822 | 0.80 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL1809800 | 0.80 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL1772581 | 0.80 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| Bromide SCHEMBL21798034 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL233616 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| EP-2035427-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-12-11 | — | — | EP | disclosed |
| EP-2520577-B1 | Pyrazolo[1,5-a]pyrimidine compounds as cb1 receptor antagonists | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-12-11 | — | — | EP | disclosed |
| EP-2520577-A1 | Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7872006-B2 | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
| EP-2035427-A2 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| WO-2008004698-A2 | PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | NPSR1 48/4885CYP4F2 3465/4885CYP4A11 1824/4885 |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | NPSR1 27/4885CYP4F2 3283/4885CYP4A11 1657/4885 |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | NPSR1 68/4885CYP4F2 893/4885CYP4A11 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.